Study of the CHK1 Inhibitor BBI-355, an ecDNA-directed Therapy, in Subjects With Tumors With Oncogene Amplifications
Status:
Recruiting
Trial end date:
2026-01-31
Target enrollment:
Participant gender:
Summary
BBI-355 is an orally available, potent, and selective checkpoint kinase 1 (or CHK1) small
molecule inhibitor in development as an ecDNA (extrachromosomal DNA) directed therapy
(ecDTx). This is a first-in-human, open-label, non-randomized, 3-part, Phase 1/2 study to
determine the safety profile and identify the maximum tolerated dose and recommended Phase 2
dose of BBI-355 administered as a single agent or in combination with select therapies.